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a b s t r a c t 
Many novel pharmaceutically active substances are characterized by a high hydrophobicity and a low water
solubility, which present challenges for their delivery as drugs. Tablets made from cross-linked hydrophobi-
cally modiﬁed poly (acrylic acid) (CLHMPAA), commercially available as Pemulen TM , have previously shown
promising abilities to control the release of hydrophobic model substances. This study further investigates
the possibility to use CLHMPAA in tablet formulations using ibuprofen as a model substance. Furthermore,
surfactants were added to the dissolution medium in order to simulate the presence of bile salts in the
intestine. 
The release of ibuprofen is strongly affected by the presence of surfactant and / or buffer in the dissolution
medium, which affect both the behaviour of CLHMPAA and the swelling of the gel layer that surrounds
the disintegrating tablets. Two mechanisms of tablet disintegration were observed under shear, namely
conventional dissolution of a soluble tablet matrix and erosion of swollen insoluble gel particles from the
tablet. The effects of surfactant in the surrounding medium can be circumvented by addition of surfactant
to the tablet. With added surfactant, tablets that may be insusceptible to the differences in bile salt level
between fasted or fed states have been produced, thus addressing a central problem in controlled delivery
of hydrophobic drugs. In other words CLHMPAA is a potential candidate to be used in tablet formulations for
controlled release with poorly soluble drugs. 
c © 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
A large amount of the novel pharmaceutically active substances
can be characterized by a high hydrophobicity and a poor water sol-
ubility [ 1 ]. Various techniques to enhance the solubility or the disso-
lution of poorly water soluble active substances have been developed
and include using solid dispersions [ 2 –4 ], particle size reduction [ 5 –
7 ], amorphous substances [ 8 ] and solubilisation using surfactants [ 9 ]
or complexes with, e.g., cyclodextrins [ 10 ]. However, there is still
a pronounced need to develop formulation concepts that allow for
controlled release of poorly soluble compounds. A common prob-
lem during formulation of a hydrophobic drug is also the differences
in the intestinal ﬂuid between fasted or fed state, which has been     
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Open access under CC BY-NC-ND licshown to affect the dissolution [ 11 , 12 ]. Today there are few strate-
gies that address these problematic food effects; examples of formu-
lations of poorly soluble drugs that circumvent food effects include
nano-particulate systems, e.g. with itraconazole [ 13 , 14 ]. In addition,
lipids have been incorporated in the formulation to trigger fed state
response [ 15 –17 ], which then increased the solubility of the drug in
the intestine and gave a higher bioavailability. Nevertheless, it is of
importance that food effects are evaluated during development of
new formulations. 
Cross-linked poly (acrylic acid) (CLPAA), commercially available
as Carbopol 
®
, has been studied extensively for use in pharmaceuti-
cal formulations, frequently because of its bioadhesive properties and
its ability to form gels. Much of the work has focused on its use as
bioadhesive tablets [ 18 –25 ], nasal applications [ 26 –30 ], ocular deliv-
ery [ 31 –33 ] and suppositories [ 34 ]. There has also been a considerable
effort studying the application of CLPAA in tablets [ 35 –38 ], which is
approved for oral formulations. In this work the Carbopol used is
Carbopol 
®
974P NF, which consist of poly (acrylic acid), cross-linked
with allylpentaerytritol. 
Pemulen TM , a commercially available cross-linked and hydropho-
bically modiﬁed PAA, (CLHMPAA) has been far less studied, mainlyense.
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Table 1 
Compositions of tablets used in this study. The SDS content was varied and when SDS 
was added the corresponding amount of lactose (in weight percent) was removed. The 
amount of ibuprofen was chosen from an experimental perspective in order to the 
match detections levels of the UV spectrophotometer. 
Ingredient Amount (wt%) 
Polymer 30 
Ibuprofen 10 
Lactose 58 / 56.75 / 54.25 / 50.5 / 45.5 / 33 
Talc 1 
Magnesium stearate 1 
SDS 0 / 1.25 / 3.75 / 7.5 / 12.5 / 25 
 ecause it currently lacks a regulatory approval to be used in oral for- 
ulations. Most of the studies have focused on topical formulations 
 39 ] but some studies have evaluated its use in tablets [ 35 , 40 , 41 ]. Fur-
hermore, a previous study showed that CLHMPAA could yield a way 
f controlling the release of poorly soluble compounds from tablets 
ormulations [ 40 ]. The substance was assumed to be incorporated 
n hydrophobic domains formed by self-assembly of the hydropho- 
ic substituents, the “hydrophobes”, of the polymer. The release was 
ustained via interactions between the hydrophobic substance and 
he hydrophobes of the polymer, which resulted in an almost ideal 
ero order release, which was not seen for a non-modiﬁed CLPAA. In 
his study, Pemulen TM TR2 NF is used. This polymer consists of poly 
acrylic acid), cross-linked with allylpentaerytritol and is hydropho- 
ically modiﬁed with grafted C10–C30 alkyl-chains. 
Paulsson and Edsman [ 42 –44 ] evaluated the release from CLPAA 
nd CLHMPAA polymer gels, and saw that a higher hydrophobicity 
f the drug resulted in a higher probability of interaction with the 
ydrophobes on the polymer. The interaction between the two could 
ecrease the rate of diffusion of the drug through the gel matrix, 
hus prolonging the release. They also saw that if surfactants were 
dded to the system, the drug molecules would partition into the 
urfactant micelles to additionally slow down their diffusion. This 
uggests that the release from tablets made from CLHMPAAs could 
e affected by the presence of surfactant and provides a possible way 
o tune the release from tablets made of CLHMPAA. On the other 
and, pronounced surfactant sensitivity could potentially aggravate 
roblems with differences in drug absorption between the fasted and 
ed states. 
The dissolution process for swellable matrix tablets is generally 
onsidered to involve solvent penetration, gel formation, swelling 
nd disentanglement of the polymer chains [ 45 , 46 ]. Three different 
oving fronts have been established, i.e. the swelling front, the dif- 
usion front and the erosion front, which determine the release rate. 
hese fronts have been thoroughly studied [ 47 –49 ] and the principles 
re summarized in a very recent review [ 50 ]. Recent studies on model 
ablets have shown that the rate of release of the polymer into the 
urrounding solution (the dissolution medium) depends on the vis- 
osity of the so-called “gel layer” (the gelatinous semi-dilute polymer 
olution that surrounds the tablet) at the boundary to the dissolution 
edium [ 47 , 51 ]. It was shown that by altering the molecular weight 
f the polymer, and hence its efﬁciency to viscosify the gel layer, the 
issolution rate of the polymer could be altered. The gel layer is gener- 
lly considered to have two functions: it slows down the dissolution 
f the tablet itself and it works as a transport barrier for the drug. 
n increased thickness of the gel layer results in a slower dissolu- 
ion of the tablet and a longer way for the drug to diffuse in order to 
e released, thus a slower drug release. In solutions of hydrophobi- 
ally modiﬁed (HM) polymers the viscosity can be altered by addition 
f surfactant [ 52 , 53 ]. Moreover, added surfactant can solubilise such 
M-polymers that, owing to extensive hydrophobic association, are 
ot soluble in water [ 52 , 54 ]. These facts indicate that the release from 
M-polymer tablets can be altered by the presence of surfactant. 
This study further investigates the possibility to use CLHMPAA in 
ablet formulations manufactured by pharmaceutically relevant unit 
rocesses. Ibuprofen is used as a model drug substance due to its hy- 
rophobic properties, in order to study the effects from hydrophobic 
nteractions. Ibuprofen is not considered (during our experimental 
onditions) poorly soluble, which circumvents solubility issues. 
The focus of this study is on the effects of adding surfactants, 
imilar to the differences in the intestinal ﬂuid between fasted or fed 
tates. In the biological system the tablets might be affected by surface 
ctive compounds such as bile salts. In this work we have examined 
he effects from addition of different types of surfactants, which either 
re allowed for oral use or are endogenous substance from bile. A 
ommon model surfactant, sodium dodecyl sulfate (SDS), was chosen 
o further examine the general effects of surface active compounds. SDS is a well-known and studied anionic surfactant, which is also 
approved for oral formulations. Furthermore, SDS is also included in 
the tablet formulation in some experiments to elucidate whether this 
can be used to alter the drug release. The rheology of semi-dilute 
CLHMPAA solutions, and the solubility of the polymer in the various 
dissolution media, has also been studied to gain additional molecular 
insight into the release mechanisms. 
2. Materials and methods 
2.1. Materials 
Pemulen TM TR2 NF (lot no. CC11MCU893) and Carbopol 
®
974P 
NF (lot no. CC23NAB431) were kindly provided by Lubrizol Chemicals. 
According to the supplier, both polymers consist of poly (acrylic acid), 
cross-linked with allylpentaerytritol, and contain 52–62% (Pemulen) 
or 56–68% (Carbopol) of COOH groups. Pemulen TM is also hydropho- 
bically modiﬁed with grafted C10–C30 alkyl-chains via ester bonds. 
From recorded 1 H NMR intensities of the terminal methyl groups of 
the alkyl grafts we deduce that a 1 wt% CLHMPAA solution contains 
ca. 4 mM of alkyl grafts (hydrophobes). 
Sodium dodecyl sulfate (SDS) was purchased from VWR Interna- 
tional (Sweden), lot no. 8Z0007176. In addition, Tween80 (lot no. 
93781) and crude bile salts (lot no. BCBJ8214V) were acquired from 
Fluka. The crude bile salt was a 50 / 50 mixture between sodium tau- 
rocholate and sodium deoxycholate. Ibuprofen sodium salt (lot nos. 
038K0755 and 87H0764) was purchased from Sigma Aldrich and used 
as delivered. The CMC for SDS is 8.3 mM in pure water [ 55 ], and with 
a tensiometer and a de No ¨uy ring, we determined the CMC to 1.8 mM 
at 37 ◦C in 0.1 M phosphate buffered solution, pH 7.2. The CMC for 
Tween80 is equal to 0.02 mM at 25 ◦C [ 56 , 57 ]. Bile salts have poorly
deﬁned CMC values, which differs between different environments, 
nevertheless it is estimated to be between 0.5 and 2 g / L [ 58 , 59 ]. 
Lactose, talc and magnesium stearate were of analytical grade. For 
granulation ﬂuid a (70:30) mixture of ethanol (99.5%) and 0.001 M 
aqueous HCl was used. 
2.2. Tablet preparation 
Tablets were prepared with compositions as speciﬁed in Table 1 , 
and the manufacturing procedure was the same for all compositions. 
First, the dry ingredients, lactose, polymer and ibuprofen (and SDS, 
where applicable) were mixed in an intensive mixer (Kitchen Aid), 
for 5 min. The granulation process started with gently spraying gran- 
ulation ﬂuid over the powder, with interruptions to allow the ﬂuid 
to absorb. The procedure was continued until the desired properties 
of the granulation were achieved. The granulation was then sieved 
through a 2 mm sieve, and if the particle size was too large, a food- 
processer was used to further reduce it. The granulation was then 
dried in an oven at 50 ◦C overnight and was afterwards sieved again 
through a 2 mm sieve. The dried granulation was mixed with talc and 
magnesium stearate in a cone blender for 2 min after each addition. 
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 The tablets were manufactured with a single-punch tableting ma-
chine, Diaf (Denmark), to a weight around 400 mg. Appropriate set-
tings were applied to ensure a good hardness and weight of the tablets.
Hardness and friability were measured according to US Pharmacopeia
methods. All tablets achieved a hardness over 5 kp and a friability less
than 1%, except for those containing high amounts of SDS ( ≥10 wt%),
which were too soft (hardness < 5 kp) and had a poor friability ( > 1%). 
2.3. Dissolution experiments 
Dissolution experiments were carried out at 37 ◦C in a USP dissolu-
tion apparatus II (Prolabo Intelligent dissolution tester Novakemilab,
Sweden) with a paddle speed of 100 rpm. Samples were continuously
withdrawn and transferred by means of a pump to a spectropho-
tometer (Cary 50 Bio UV–visible, Varian, Australia) which measured
the ibuprofen concentration in the vessels as the absorption at λ
= 222 nm. From the measured UV absorbance the concentration of
ibuprofen and, hence, the fraction released in the dissolution medium,
could be determined. 
Each USP vessel was ﬁlled with 800 mL of dissolution medium.
The media used were 0.1 M phosphate buffered solution, pH 7.2, and
water deionised in a Milli-Q water apparatus. The pH of the water so-
lution was not monitored during dissolution nevertheless it is likely
that pH will change during dissolution. Tween80 and bile salts were
added to buffered solution in the following concentrations 10 g / L and
7.14 g / L respectively (similar to the conditions in the intestine at fed
state [ 60 ]). For SDS varying amounts were added, yielding concentra-
tions between 0–10 mM (phosphate buffered solution) and 0–20 mM
(Milli-Q water). The amount of SDS added to the tablets represents
a concentration in the bath of maximum 0.4 mM, which is below
the CMC for SDS. Tablets were weighed prior to the start of the ex-
periments. From this the total amount of ibuprofen in a tablet was
calculated. 
For tablets dissolving in Tween80 and crude bile salts the ab-
sorption from the spectrophotometer could not be used due to the
large absorbance from the solutions. Instead aliquots ( V = 1 mL) were
manually withdrawn from each vessel at speciﬁed time intervals and
analyzed with HPLC (HP Series 1050), using a ﬂow of 0.4 mL / min on
a reversed phase Acclaim RLSC C18 2.2 μm, 120 A˚, 2.1 × 50 mm 2
column. The HPLC detected the ibuprofen as the UV absorption at
λ = 222 nm. For samples containing Tween80, an isocratic solution
with 40% ACN and 60% water with 0.1% acetic acid was used. Samples
containing bile salts were mixed with AcN prior to analysis (50 / 50
mixture) and analysed with an isocratic solution of 35% ACN and 65%
water with 0.1% acetic acid. 
% R e le ase = ( C ibu × ( V 0 − V s ×n s ) + 
∑ 
ns ( V s ×C s ) ) 
m ibu , tab le t 
(1)
The released amount (%released) was calculated according to Eq.
2.5.1, where the concentration of ibuprofen according to the HPLC is
given by C ibu and the initial volume of the vessel is V 0 ( = 800 mL). V s
and C s denote the volume ( = 1 mL) and the concentration in the
samples respectively and the number of samples is denoted n s . The
amount of ibuprofen in the tablets is given by m ibu,tablet . All experi-
ments, if not stated otherwise, were performed at least two times in
order to validate reproducibility. 
2.4. Rheology 
2.4.1. Sample preparation 
Rheology experiments were conducted on systems of 1 wt% CLHM-
PAA in either deionised water or in 0.1 M phosphate buffered solution
at varying concentrations of added SDS. The procedure was the same
for both types of dissolution media. A stock SDS solution was diluted
to the desired concentration, and then CLHMPAA was added to give
1 wt% concentration of polymer. For samples prepared in bufferedsolution, 2 M NaOH-solution was used to adjust the pH to 7, after
addition of polymer. Care was taken to ensure that the same amount
of NaOH was added to each sample, yielding equal ionic strength.
The pH of each sample was conﬁrmed prior to analysis. After addi-
tion of polymer all samples were agitated and put on a tilt table until
analysed. The samples were also repeatedly mixed manually with a
spatula and centrifuged directly afterwards. All samples were mixed
for 1 week to ensure that equilibrium had been reached. Prior to anal-
ysis, the samples were centrifuged to eliminate air bubbles formed
during the mixing. All samples were prepared in triplicate. 
2.4.2. Oscillatory rheology measurements 
The measurements were carried out on a controlled stress
rheometer (StressTech IMP5040, Reologica, Viscotech). Cone-plate
symmetry with a diameter of 40 mm was used and the temperature
was set to 37 ◦C. All experiments started with equilibration of the
sample for 60 s, followed by a stress sweep at 1 Hz between 0.2 and
200 Pa in 50 logarithmic steps. Directly afterwards a frequency sweep
between 0.005 and 10 Hz at a constant stress of 1 Pa was performed.
The frequency-dependent complex viscosity ( η*) was obtained from 
η∗ = G  
∗
ω 
= 
[ 
( G  ′ ) + ( G  ′′ ) 2 
] 1 / 2 
ω 
(2)
where G ′ is the storage modulus, G ′′ is the loss modulus and ω is the
frequency of oscillation. 
3. Results 
3.1. Dissolution of HMPAA tablets in different media 
The release of ibuprofen from tablets made from CLHMPAA is gen-
erally characterized by a slow and linear release proﬁle ( Figs. 1 and
2 ) throughout the dissolution process and the release was faster in
water than in buffered solution Addition of surfactant to the dissolu-
tion medium slowed down the release further, however retaining the
linear release. The different surfactants used reduce the release rate
in a similar manner and to a similar extent, in Fig. 1 , all surfactants
are added in concentrations over the CMC. Examining the dissolv-
ing tablets visually shows that the tablets form larger gel layer upon
addition of buffer and surfactants. However, upon addition of bile
salts a clear gel layer is not formed, instead the tablets were cloudy
nonetheless swollen. Moreover studies have been performed, where
the release of lactose from the tablets has been quantiﬁed using a new
analytical method, which will be published soon. These show that the
lactose (a hydrophilic model substance) is quickly released from the
tablet, and the release is less affected by the presence of surfactants. 
Examining the release rate for different concentrations of SDS
there is a discrepancy between the buffered solution and water below
concentrations of 7 mM ( Fig. 2 ). On the other hand, above 7 mM SDS,
the rate was similar and very slow in both media and here the tablets
were not fully dissolved after 67 h. In some cases the tablets appeared
to release more than 100% when fully dissolved; this is most likely
due to solvent evaporation during the extended dissolution time. The
amount of polymer in the tablets is high in these experiments; a low-
ering of the polymer concentration will increase the release rate but
also make the experiments sensitive to polymer concentration. Thus
all the work done here is performed at a polymer concentration high
enough to avoid this sensitivity. 
In order to compare the release rates for different concentrations
of SDS in the various dissolution media, the release rate at 20% re-
leased amount (R-20) was evaluated from each release proﬁle by
a linear ﬁt to 10 data points centred around 20% released amount.
The choice of 20% is somewhat arbitrary, but owing to a very slow
release, a few experiments had reached less than 50% of released
ibuprofen at termination, see Fig. 2 . The R-20 data are collected in
10 Patrik Kn o¨ o¨s et al. / Results in Pharma Sciences 3 (2013) 7–14 
Fig. 1. Release of ibuprofen from CLHMPAA tablets into different solutions containing 
pure water and buffer (0.1 M, pH = 7.2) as well as buffer with added surfactants 
(SDS, Tween80 and bile salts) as noted in the ﬁgure. Each dataset represents one 
measurement and is shown as representative data. The released amount is normalized 
against the released amount for fully dissolved tablets, i.e. released amount at t end = 
100%. Lines without data points represent measurements every 20th minute up to 6 h 
and after that measurement each hour. 
Fig. 2. Release of ibuprofen from CLHMPAA tablets in water (A) and buffered solution 
(0.1 M, pH = 7.2, B) without and with added SDS at the indicated concentrations. The 
release is compared to the release of ibuprofen without addition of surfactant (0 mM 
SDS). Each dataset represents one measurement and is shown as representative data. 
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Fig. 3. Slopes of ibuprofen release proﬁles at 20% released amount for tablets dissolving 
in buffered solutions (0.1 M, pH = 7.2, ﬁlled) and water (open) at varying concentrations 
of SDS added to the dissolution media. Each symbol represents one measurement and 
the lines are drawn through the average values. Vertical lines show the critical micelle 
concentrations of SDS in buffered solution and in pure water. ig. 3 , which clearly illustrates the effects of the buffer and / or sur- 
actant added to the dissolution media. In either medium, the release 
f ibuprofen was hardly affected by the presence of surfactant in a 
ow-concentration plateau region, below a concentration of ca. 2–
 mM SDS. Above the latter concentration, the ibuprofen-release rate 
ecreased rapidly with added SDS until a second high-concentration 
lateau was reached. The concentration of SDS at the onset of the 
igh-concentration plateau coincides quite well with the critical mi- 
elle concentration, CMC, of SDS in both buffered solution and pure 
ater. There was a strong effect of the buffer at zero and low concen- 
rations of SDS, whereas the release rate at the high-concentration 
lateau was insensitive to the presence of the buffer. 
The tablets were observed visually during dissolution in the 
edium with SDS and sample tablets were also taken out of the 
issolution medium. All dissolving tablets were surrounded by trans- 
arent gel layers and in the middle of the tablet a white “core” could 
e seen; closer examination showed that this core was not solid but 
ather had a sponge-like texture. The gel layers of the tablets gen- 
rally increased in thickness with increasing SDS concentration, but 
arge differences in the dissolution behaviour in water and buffered 
olution were observed at low SDS concentrations. In water a clear 
ut very thin gel layer developed and the tablet had a rough surface 
rom which semi-swollen particles, visible to the naked eye, eroded 
uring dissolution. The latter feature disappeared when the SDS con- 
entration had reached the high-concentration plateau; here a thick, 
mooth gel layer developed. In buffered solution, a sizeable gel layer developed already without SDS, and no eroding particles were de- 
tected visually at any SDS concentration. 
3.2. Physico-chemical behaviour of CLHMPAA in different media 
In order to better understand the dissolution and drug release be- 
haviour in the various systems, we performed additional studies of 
the physico-chemical behaviour of CLHMPAA in the various media. 
One series of simple experiments addressed the solubility of CLHM- 
PAA. From a physico-chemical point of view, Pemulen TM consists of 
huge cross-linked polymer molecules that may either dissolve in, or 
phase separate from, a given solvent. To test this we made up a se- 
ries of dilute mixtures of CLHMPAA in the various dissolution media. 
The concentration (0.015 wt%) of these dilute mixtures was chosen 
to be equal to the concentration at complete dissolution in the dis- 
solution experiments. The samples were then agitated and put on a 
tilt-table for a period of 1 week and were subsequently subjected to 
centrifugation (1 h at 5000 rpm). 
CLHMPAA did not dissolve in pure water, but formed a cloudy 
dispersion of swollen gel particles that could be separated by cen- 
trifugation. On addition of 1–2 mM SDS, the cloudiness disappeared, 
but centrifugation still resulted in the separation of the polymer, this 
time as a clear, gelatinous bottom phase. At and above 5 mM SDS in 
water, ﬁnally, the polymer appeared totally dissolved and no polymer 
separated out on centrifugation. In buffered solutions clear samples 
were obtained both with and without SDS, but centrifugation resulted 
in the separation of a clear, polymer-rich bottom phase at SDS con- 
centrations at or below 2 mM. Above 2 mM SDS in buffered solution, 
CLHMPAA was again found to be soluble. 
We also measured the viscosity of CLHMPAA in the various media. 
The measurements were done at higher concentrations (1 wt%) of the 
polymer, to probe conditions that should be more relevant for the gel 
layers surrounding the tablets. Since the concentration of carboxylic 
acid groups from the polymer was comparable to the concentration 
of phosphate buffer in the buffered systems, the buffer alone did not 
succeed in maintaining a pH around 7. Therefore, the pH for these 
systems was adjusted to 7 ± 0.2 by addition of 2 M NaOH, again to 
mimic the situation in a gel layer exposed to a large reservoir of buffer 
at pH 7.2. The resulting systems were in all cases highly viscous. 
Fig. 4 shows the complex viscosities at 0.2 Hz of 1 wt% CLHM- 
PAA in water and buffered solution plotted against the concentration 
of added SDS. In both media, the viscosity varied signiﬁcantly with 
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Fig. 4. Complex viscosity* ( η*) (at 0.2 Hz) for 1 wt% CLHMPAA in buffered solution 
((0.1 M, pH = 7.2, pH = 7) (ﬁlled) and water (open) with increasing SDS concentration. 
Error bars indicate the standard deviation ( n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. The release of ibuprofen from CLPAA tablets in buffered solution (0.1 M, pH = 
7.2) containing pure buffer (0 mM SDS), 3 mM and 10 mM SDS. Each dataset represents 
one measurement and is shown as representative data. 
Fig. 6. The release of ibuprofen in buffered solution (0.1 M, pH = 7.2) from tablets of 
CLHMPAA containing 7.5 wt% SDS (SDS in tablet), compared with tablets with no SDS 
(without SDS). The lines represent repeat measurements on different tablets performed 
at the same time and illustrate the experimental reproducibility. Lines represent mea- 
surements every 20th minute up to 6 h and after that measurement each hour. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 the SDS concentration, clearly revealing an interaction between SDS
and CLHMPAA. Mixtures prepared in water solution consistently dis-
played a lower viscosity compared to the buffered systems, but the
two sets of results approach each other at high surfactant concentra-
tions. 
3.3. Additional dissolution experiments 
3.3.1. Tablets of non-modiﬁed cross-linked PAA 
For reference, we also studied the release of ibuprofen into
buffered solution from dissolving tablets made from non-modiﬁed
CLPAA, see Fig. 5 . The latter behaved differently from those made
from CLHMPAA. The CLPAA tablets developed a very thin gel layer
and disintegrated faster, with small gel particles eroding continu-
ously from the tablets. These tablets were fully dissolved after ca.
340 min. Visually there was no obvious effect of SDS added in the
dissolution medium on the size and shape of the gel layer, nor on the
erosion of gel particles. The non-modiﬁed tablets also gave a faster
release of ibuprofen, compared to the CLHMPAA tablets, but the re-
lease was still linear. Although the effects of added SDS on the release
are largely lost for tablets without hydrophobes, closer examination
reveals a small decrease in the release rate on addition of surfactant
to the release medium. 
3.3.2. CLHMPAA tablets containing added SDS 
In a ﬁnal set of experiments, we studied the dissolution and re-
lease from CLHMPAA tablets that also contained SDS. Small additions
of SDS to the tablets did not result in large changes in tablet proper-
ties during production, except an increased sensitivity during solvent
addition during granulation, and tablets with satisfying properties
were achieved. However, if the amount of SDS in the tablet was in-
creased above 7.5 wt%, a soapy granulation was obtained, which with
our equipment resulted in poor tablets with a low hardness and poor
friability. In all cases the total amount of SDS added to the tablets
was lower than the lowest total amount of SDS that was added to the
dissolution media in the previous set of experiments. 
The effect of adding SDS to the tablet on the release of ibuprofen
into buffered solution was similar to the effect of adding surfactant
to the release medium. A slow linear release was observed that ex-
tended over days, see Fig. 6 . Adding increasing amounts of SDS to the
tablet decreased the release rate, until a point where the tablet and
granulation properties became unsatisfying. SDS added to the tablet
increased the thickness of the gel layer, again similar to the effect of
adding SDS to the dissolution medium. Further investigating the effects of surfactants on the release, SDS
was added also to the medium during the dissolution of SDS-loaded
tablets. Two different concentrations of SDS in the buffered solutions
were used, one at the low-concentration plateau seen in Fig. 3 and one
at the high-concentration plateau. As illustrated in Fig. 7 , there were
no apparent effects on the ibuprofen release from the SDS-loaded
tablets of adding SDS to the dissolution medium: the already slow
release was retained. 
To further investigate surfactant effects the release from CLH-
PMPPA tablets with SDS in media containing Tween or Bile salt was
investigated. As can be seen the proﬁle is quite similar as for the pure
buffer or SDS media. The release could be somewhat slower but one
should keep in mind that these experiments were performed with
another batch of tablets and using a different analytical method. It
has been observed that the UV analyses usually give a ﬁnal amount
released that is slightly above 100% but that the HPLC measurements
normally only give 100% of release. 
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Fig. 7. R-20 values in buffered solution (0.1 M, pH = 7.2) for tablets of CLHMPAA that 
contained indicated amounts of added SDS. Points marked with an asterix represent 
tablets that did not fulﬁl the requirements regarding hardness and friability. Error bars 
represent the standard deviation of the measurements ( n > 2). 
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s. Discussion 
The aim of the present study was to elucidate the consequences of 
ydrophobic modiﬁcation on the behaviour of PAA-based tablets in 
ifferent media. Our major ﬁndings may be summarised as follows. 
1) Hydrophobic modiﬁcation generally gives rise to a slower ibupro- 
en release from a CLPAA-based tablet, and to a marked surfactant 
ensitivity of the release. (2) Added surfactant, either dissolved in the 
edium or incorporated in the tablet, makes the release even slower 
ntil a plateau is reached at high surfactant levels. (3) With surfactant 
ncorporated in the tablet, the ibuprofen release becomes insensitive 
o surfactant added in the dissolution medium. We will now attempt 
o understand these features in the light of prior knowledge as well 
s the additional observations made in this study. 
Established knowledge on aqueous mixtures of HM-polymers and 
urfactants may be summarized as follows [ 54 ]: the hydrophobes of 
M-polymers typically self-associate in water, leading to a high vis- 
osity of their semi-dilute aqueous solutions, but also to a decreased 
ater solubility. Charged HM-polymers are more soluble than un- 
harged ones, other factors being equal. When surfactant is added to 
 HM-polymer in water, the surfactant molecules enter into the ag- 
regates of the hydrophobes, forming mixed micelles of hydrophobes 
nd surfactant molecules. At low fractions of incorporated surfac- 
ant molecules, their effect is mainly to strengthen the pre-existing 
ydrophobic association between the polymer molecules. With in- 
reasing levels of surfactant, however, the number of mixed micelles 
ncreases and, eventually, all hydrophobic cross-linking is lost as the 
olymer hydrophobes are solubilised in the abundant surfactant mi- 
elles. 
In Fig. 3 , the rheology of 1 wt% CLHMPAA in buffered solutions at 
H 7 illustrates the typical response of a water-soluble HM-polymer 
o added surfactant [ 52 –54 ]: at low levels, the viscosity increases 
strengthening of the hydrophobic association) but eventually, the 
iscosity decreases again, owing to a dissolution of the hydrophobic 
olymer–polymer association. The water solubility of the HMPAA is 
ere achieved by a large fraction of charged carboxylate groups at 
H 7. In unbuffered water, on the other hand, the initial rheological 
esponse of the essentially uncharged CLHMPAA to added surfactant 
s typical of a system with water-swollen, but insoluble, hydrophobi- 
ally modiﬁed polymer aggregates. Here, the initial strengthening of 
he hydrophobic association leads to a de-swelling of the polymer–
urfactant aggregates and, hence, a decrease in viscosity. At high levels of surfactant, solubilisation of the hydrophobes in the surfactant mi- 
celles make the CLHMPAA / SDS aggregates soluble in water both with 
and without buffer. 
We note that the mixtures investigated by rheology in Fig. 4 are not 
directly comparable to the dissolving tablets, since the latter systems 
are connected to a large reservoir of surfactant and buffer. Owing to 
the binding of surfactant to the HMPAA hydrophobes, the total con- 
centration of surfactant in the outer part of a gel layer surrounding 
a tablet may be substantially higher than the concentration in the 
surrounding reservoir. On the other hand, our simple solubility tests, 
which were made in dilute systems, should be directly comparable to 
the tablet dissolution experiments. In the solubility tests, we found 
that both in water and in buffered solution, a complete dissolution 
of CLHMPAA required surfactant concentrations of the order of the 
surfactant CMC or higher. We also saw that the CLHMPAA-rich phase 
that separated out at zero or low levels of surfactant was much more 
swollen in buffer than in unbuffered water, a difference that we at- 
tribute to the difference in polymer charge. 
The varying water solubility of HMPAA and its complexes with 
SDS, and the varying water uptake of those complexes that separate 
out of the solution, should have profound consequences for the dis- 
integration of the tablets and the drug release. For dissolution media 
at high surfactant concentrations we have the common case of a sol- 
uble polymer that can swell indeﬁnitely in the dissolution medium. 
The situation should then be similar to, e.g., poly (ethylene oxide) 
tablets dissolving in water, which have been studied in detail [ 47 , 51 ]. 
For the latter systems, it was concluded that the disintegration of 
the tablets was governed by the viscosifying efﬁciency of the poly- 
mer. For the very viscosifying HMPAA studied here (see Fig. 4 ), a 
thick gel layer develops and tablet disintegration and drug release 
become very slow. At high surfactant concentrations, the observed 
plateau release rate (see Fig. 3 ) then suggests that the viscosity of the 
system has become insensitive to further surfactant addition. This is 
indeed expected when the concentration of surfactant in the medium 
has reached CMC; then free micelles form, the surfactant monomer 
concentration remains approximately constant, and there is little ad- 
ditional surfactant binding to the complex. 
At low surfactant concentrations, CLHMPAA is not soluble in the 
investigated media, and this means that the gel layer around the 
tablet can only swell until it reaches the composition of the polymer- 
rich phase that would separate out at equilibrium when polymer is 
added to the same medium. When such a gel layer is subjected to 
shear, pieces of the swollen but insoluble gel layer will be sheared 
off, as was indeed observed in the release experiments. The erosion 
of small gel particles not only speeds up the disintegration of the 
tablet itself, but also the release of the drug, since the drug release 
from many small gel particles, with a large speciﬁc surface area, is 
much more rapid than the release from a single macroscopic tablet. 
A comparison between surfactant-free water and buffered solution 
as dissolution media show that the maximum degree of swelling of 
the concentrated phase is also important for the tablet disintegration 
and the drug release. In the buffer the PAA chains are partly charged 
and the maximum swelling is larger, compared to the situation in un- 
buffered water. This results in a thicker gel layer in buffered solution, 
leading to a less efﬁcient disintegration of the tablet by shear (less 
polymer is removed per unit time), and a slower drug release. 
An alternative way to produce soluble HM-polymer / surfactant 
complexes is to incorporate a sufﬁciently high level of surfactant in 
the tablet, as in the release experiments in buffered solution sum- 
marized in Figs. 6 –8 . Although surfactant should be released from 
the tablet and thus from the complexes, this is a slow process since 
the concentration of uncomplexed surfactant in the tablet gel layer 
must be of the order of CMC (2 mM in buffered solution) or less. With 
sufﬁcient levels of surfactant in the tablets, the release also becomes 
insensitive to the presence of surfactant in the bulk ( Fig. 8 ). 
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Fig. 8. Release of ibuprofen in buffered solution (0.1 M, pH = 7.2) from tablets of 
CLHMPAA with SDS added to the tablet (7.5 wt%) and with surfactants added to buffer 
solution, SDS (A), Tween80 and bile salt (B) at the indicated concentrations. Each dataset 
represents one measurement and is shown as representative data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 We are now in the process of trying to further understand the re-
lease mechanisms behind the seen results. Our hypothesis is that sol-
ubilisation of the active substance into micelles will reduce transport
in Pemulen as micelles aggregate on the hydrophobes of the polymer.
One further explanation could be that the micelles and polymer ag-
gregates change the rheology of the polymer and thus the dissolution
of the polymer. 
Tablets with CLPAA in buffered solution showed similar dissolu-
tion characteristics as CLHMPAA in pure water: the tablets did not
seem to dissolve and small pieces of cloudy semi-swollen particles
eroded from the tablets. The low solubility of CLPAA was indeed con-
ﬁrmed by mixing 1 wt% CLPAA in buffered solutions, which resulted
in cloudy dispersions. Since CLPAA lacks hydrophobes that interact
strongly with SDS, there was no strong effect of SDS added in the
dissolution medium on the dissolution and drug release of the CLPAA
tablets. 
5. Concluding remarks 
In this study we have elucidated important effects of polymer
hydrophobic modiﬁcation and of added surfactant, separately and
combined, on the disintegration and release properties of polymer
matrix tablets, and we have also proposed mechanistical explana-
tions to the observed effects. From a more practical point of view, we
conclude that CLHMPAA is a potential candidate to be used in tablet
formulations for controlled release with poorly soluble drugs. Tablets
containing ibuprofen and CLHMPAA have a slow and almost ideal lin-
ear release, which is kept until the tablet is completely disintegrated.
The release times seen in these experiment are very long and fur-
ther optimisations need to be done for the formulation to be used in
vivo. However the tablets give indications as to how the release of
the different tablets would be in in vivo and, more speciﬁcally, how
it could be affected by the presence of surface active compounds, for
example bile salts. We note that the tablets contain a high amount of
polymer (30 wt%) and that preliminary experiments have shown that
by decreasing the amount of polymer the extended release time can
be decreased (unpublished data). 
The release is strongly affected by the presence of surfactant and /
or buffer, which affects both the solubility of CLHMPAA and the max-
imum swelling of the gel layer that surrounds the disintegrating
tablets. Importantly, two mechanisms of tablet disintegration were
observed under shear, that is, conventional dissolution of a soluble
tablet matrix or erosion of swollen insoluble gel particles from the
tablet. 
Interestingly, the effects from surfactant in the surrounding
medium can be circumvented by addition of surfactant to the tablet.
With added surfactant, tablets that might not be susceptible to the
differences in bile salt level between fasted or fed states have been
produced. This should be further evaluated using simulated intestinal
ﬂuid, e.g. FaSSIF / FeSSIF, which could also include optimisation of theextended dissolution time. This suggests that the potential of CLHM-
PAA and surfactant in tablet formulations is high and that further
studies should be conducted. This includes optimising the content of
Pemulen to give a desired time frame of release as well as obtaining
approval for oral use of the polymer. 
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